This study found that nearly 17 million adolescents and young adults were eligible for glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy. One in 5 young adults eligible for GLP-1RAs were ...

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

Study Rundown: Studies have suggested that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of various forms of dementia, including vascular dementia and Alzheimer’s disease.

Glucagon-like-peptide-1 agonists like Ozempic have become extremely popular for weight loss. Here are some of the side effects you should know about.

About The Study: In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated with a 2-fold higher risk of incident ...

Glucagon-like peptide-1 (GLP-1) agonists, widely used for glycemic control and weight loss in type 2 diabetes mellitus (T2DM), have demonstrated cardiovascular, renal, and anti-cancer benefits, ...

Given the scope of the risk, attention has turned to metabolic hormones that regulate appetite, satiety, and glucose metabolism, particularly glucagon-like peptide-1 (GLP-1).

1. In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk of depression compared with dipeptidyl peptidase-4 inhibitors among older ...

Glucagon-like peptide-1 receptor (GLP-1R) agonists, originally developed for type 2 diabetes patients and popularized by their ability to rapidly reduce body weight in patients with obesity, have ...